Carnegie acted as financial adviser in the rights issue of SEK 225 million in Medivir. The new funds will be used to strengthen the capital base of Medivir, allowing the group to focus further on its prioritised projects. Medivir is an innovative, specialist research company which develops drugs with the objective of becoming a sustainably profitable pharmaceuticals company. February, 2007.
Healthcare
Rights issue in Medivir (SE) — SEK 225 million
February 2007